This is an observational, cohort study that will use secondary data to describe the baseline demographics and clinical characteristics in patients who received EVUSHELD as PrEP against SARS-CoV-2 infection/COVID-19 in Japan.
All patients who have a record of administration of EVUSHELD in the database will be included in the study. The index date will be defined as the date of first EVUSHELD administration in the database (Day 0) and the patients will be followed up to 6 months after the index date (Day 1 to 180). The look back period is defined as the 12-month period prior to index date (Day -360 to -1). The exposure of interest will be defined as the administration of EVUSHELD for use as PrEP against COVID-19. As the result of feasibility assessment, sample size of the study expected to be approximately 280.

开始日期2023-12-06

申办/合作机构

AstraZeneca PLC

NCT05465876

/ Withdrawn临床2期IIT

A Multi-Center, Open-Label, Single-Arm Phase II Trial of Antibody Combination EVUSHELD (Tixagevimab and Cilgavimab) to Provide Passive Immunity Against COVID-19 in Vaccine Non-responsive Chronic Lymphocytic Leukemia

Chronic lymphocytic leukaemia (CLL) is a common lymphoid malignancy affecting older adults. CLL patients are immunocompromised by the disease itself and by several of its therapies. It has now been shown that many CLL patients do not mount an antibody response following COVID-19 vaccination and are therefore at risk of COVID-19 infection. Furthermore, patients with hematologic malignancies are known to be at increased risk of severe infection if they do acquire COVID-19 infection.
The purpose of this trial is to document evidence of passive immunity to COVID-19 infection after EVUSHELD administration with serologic and neutralization assays at multiple post administration time points in patients with no response to standard of care vaccination to COVID-19.
This trial will include a single dose of EVUSHELD to be administered, with a 1-year follow-up period, comprising of 8 health status visits.
Blood samples will be taken at screening, baseline and at multiple health status visits over the course of the year for various antibody testing and analysis. T cell reactivity to COVID-19 epitopes will be studied at baseline and again monthly for 3 months in any participants that become infected with COVID-19.

开始日期2023-10-01

申办/合作机构

Sunnybrook Health Sciences Centre

[+1]

NCT05569408

/ CompletedN/A

An Observational Study to Assess the Real-world Effectiveness of EVUSHELD™ (Tixagevimab/Cilgavimab) as Pre-exposure Prophylaxis Against COVID-19 Among EVUSHELD-eligible Populations in the United States Department of Defense Healthcare System

An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and other COVID-19 related outcomes in the total EUA-eligible patient population treated in DoD Health system.

开始日期2023-08-10

申办/合作机构

AstraZeneca PLC

100 项与西加韦单抗/替沙格韦单抗相关的临床结果

登录后查看更多信息

100 项与西加韦单抗/替沙格韦单抗相关的转化医学

登录后查看更多信息

100 项与西加韦单抗/替沙格韦单抗相关的专利（医药）

登录后查看更多信息

170

项与西加韦单抗/替沙格韦单抗相关的文献（医药）

2025-03-03·JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-omicron or omicron variants: a modelling analysis of the randomized DisCoVeRy trial—authors’ response

Communications

作者: Beaulieu, Maxime ; Guedj, Jérémie

2025-03-03·JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Comment on: Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial

Communications

作者: Lesgards, Jean-François ; Reverbel, Corinne ; Azalbert, Xavier ; Guillaume, Gérard ; Lacout, Alexis ; Perronne, Christian ; Cerdan, Dominique ; Lounnas, Valère ; Zizi, Martin

2025-02-01·LANCET INFECTIOUS DISEASES

Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial

Article

BACKGROUND:

Sipavibart is an anti-spike monoclonal antibody that neutralises SARS-CoV-2 with exceptions, including Phe456Leu-containing variants (eg, KP.2* and KP.3*). This trial assessed sipavibart efficacy and safety for prevention of symptomatic COVID-19 in participants who are immunocompromised.

METHODS:

In this ongoing, double-blind, international, phase 3 trial, we enrolled participants who were immunocompromised and aged 12 years or older at 197 hospitals, university health centres, and clinical trial units in 18 countries. Participants were randomly allocated 1:1 to a sipavibart group (intramuscular sipavibart 300 mg on days 1 and 181) or a comparator group (tixagevimab 300 mg-cilgavimab 300 mg on day 1 and placebo on day 181 or placebo on days 1 and 181), stratified by previous COVID-19 vaccination and infection status and use of tixagevimab-cilgavimab. The primary efficacy outcomes were symptomatic COVID-19 caused by any variant or symptomatic COVID-19 caused by non-Phe456Leu-containing variants within 181 days of dosing, assessed in the SARS-CoV-2-negative set, comprising all participants without a positive RT-PCR test for SARS-CoV-2 at baseline and who received at least one trial intervention dose. Safety outcomes for adverse events were assessed 90 days following the first dose and for serious adverse events throughout the study in the safety analysis set (ie, all participants who received at least one injection of sipavibart or comparator). This study is registered with ClinicalTrials.gov, NCT05648110.

FINDINGS:

Participants were screened from March 31 to Oct 27, 2023; 3349 participants (56·8% female) were randomly assigned: 1674 to the sipavibart group (five no first dose; 1669 sipavibart) and 1675 to the comparator group (nine no first dose; 1105 tixagevimab-cilgavimab and 561 placebo). Within 181 days of dosing, 122 (7·4%) of 1649 participants in the sipavibart group and 178 (10·9%) of 1631 participants in the comparator group had symptomatic COVID-19 due to any variant (relative risk reduction [RRR] 34·9% [97·5% CI 15·0 to 50·1]; p=0·0006), 54 (3·3%) participants in the sipavibart group and 90 (5·5%) participants in the comparator group had symptomatic COVID-19 due to non-Phe456Leu-containing variants (RRR 42·9% [95% CI 19·9 to 59·3]; p=0·0012), and 47 (2·9%) participants in the sipavibart group and 64 (3·9%) participants in the comparator group had symptomatic COVID-19 due to Phe456Leu-containing variants (30·4% [-1·8 to 52·5]). Adverse events occurred in 833 (49·9%) of 1671 participants in the sipavibart group and 857 (51·5%) of 1663 participants in the comparator group within 3 months of the first dose. One COVID-19-related death occurred in the comparator group. Serious adverse events considered related to trial intervention occurred in two (0·1%) of 1671 participants in the sipavibart group and seven (0·4%) of 1663 participants in the comparator group (none fatal). No serious cardiovascular or thrombotic events were considered to be related to sipavibart.

INTERPRETATION:

The primary analysis showed efficacy and safety of sipavibart in preventing symptomatic COVID-19 in participants who are immunocompromised when susceptible (ie, non-Phe456Leu-containing) variants dominated, although no efficacy was shown against resistant (ie, Phe456Leu-containing) variants that dominate as of November, 2024.

FUNDING:

AstraZeneca.

170

项与西加韦单抗/替沙格韦单抗相关的新闻（医药）

2025-04-08

·astrazeneca.com

AstraZeneca showcases innovation in infectious disease protection at ESCMID Global 2025

AstraZeneca will share new data across its Vaccines & Immune Therapies portfolio at the 2025 Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) in Vienna, Austria, from 11-15 April 2025. With 13 abstracts, including two oral presentations and two late-breaking poster presentations, the Company will highlight progress in advancing novel immunisations against bacterial and viral infectious diseases and share real-world evidence showing the burden of respiratory viral infections and the continued need for protection. Benjamin Moutier, Senior Vice President, Vaccines & Immune Therapies, AstraZeneca said: “AstraZeneca is building an innovative portfolio of antibodies and vaccines to tackle two of the top global public health threats – serious bacterial infections and respiratory viral infections. At ESCMID, we’ll share data on three novel monoclonal antibodies targeting high-priority pathogens, highlighting our ambition to redefine care for serious bacterial infections. In addition, we will present 20 years of effectiveness data for Fluenz/FluMist, as well as real-world data highlighting the ongoing burden of RSV and hMPV, two leading causes of respiratory illnesses.” Advancing potential new options for serious bacterial infection prevention and treatment Serious bacterial infections pose significant and growing threats to global health, linked to an estimated 7.7 million deaths a year globally, leading to increasing morbidity and mortality for patients and a substantial burden on health systems.1 At ESCMID, the Company will share preclinical data on investigational monoclonal antibodies (mAbs) targeting three of the top five pathogens identified as urgent risks by the Centers for Disease Control and Prevention: Staphylococcus aureus (S. aureus): Oral presentation on in vivo expression of an mRNA-encoded multi-mechanistic mAb combination against S. aureus. There are millions of methicillin-resistant S. aureus (MRSA) infections annually worldwide, and MRSA is resistant to many types of antibiotics, making treatment highly complex. A pathogen-specific treatment strategy with mAbs targeting some S. aureus virulence factors represents an alternative to broad spectrum antibiotics.2 Pseudomonas aeruginosa (P. aeruginosa): Preclinical data showing that gremubamab, an anti-P. aeruginosa bispecific human mAb, may enhance neutrophil-mediated killing of P. aeruginosa in bronchiectasis patients. P. aeruginosa is a pathogen that colonizes one-third of patients with bronchiectasis, a chronic lung condition impacting about one million people globally and drives significant disease morbidity and mortality.3 Klebsiella pneumoniae (K. pneumoniae): Research on the development and characterisation of bispecific antibodies that protect against bacteraemia and pneumonia from the major serotypes of antibiotic-resistant K. pneumoniae in mouse models. Infections caused by K. pneumoniae are responsible for more than 700,000 yearly deaths worldwide.4 Real-world data examining the impact of respiratory infections AstraZeneca is presenting 20 years of real-world data on Fluenz/FluMist (live attenuated influenza vaccines, LAIV), recently approved in the U.S. as the only vaccine for self- or caregiver administration for the prevention of influenza, demonstrating long-term effectiveness comparable to that of inactivated (IIV) influenza vaccines in children.5 The Company will also present two late-breaking posters featuring real-world studies in patients with haematological malignancies who are highly susceptible to severe respiratory infections. The studies show that outcomes from human metapneumovirus (hMPV) and respiratory syncytial virus (RSV) were similar to those from influenza and COVID-19, highlighting the need for development of novel options for preventing disease caused by hMPV and RSV.6,7 Retrospective analyses from Valencia, Spain, where there is systematic testing for multiple respiratory viruses, highlight the impact of RSV and influenza on severe disease and mortality in older adults throughout the COVID-19 pandemic, and suggest a potentially greater proportion of mechanical ventilation use and in-hospital death from RSV than influenza in adolescents and adults.8,9 Additional real-world data from France highlight the extensive healthcare resource utilisation due to hMPV and RSV and underline the need for routine testing for hMPV to accurately assess its true burden.10 Additionally, data being presented by our partner, Sanofi, confirm the significant public health impact and real-world effectiveness of Beyfortus in reducing RSV disease and hospitalisations in infants.11 Furthering Research in COVID-19 Prevention Data on AZD6563, an investigational novel COVID-19 mRNA vaccine-like particle (VLP) vaccine, demonstrating that a low dose may elicit equivalent cell-mediated immunity to a licensed mRNA vaccine will also be shared.12 Additionally, data will be presented increasing confidence in a SARS-CoV-2 variant-agnostic threshold which could be used as a surrogate endpoint for benchmarking expected efficacy of novel mAbs for the prevention of COVID-19 against emerging variants.13 Key AstraZeneca presentations during ESCMID 2025 Abstract Title Presentation Details Abstract Title Early Science: Serious Bacterial Infections and Respiratory Viral Infections Abstract Title In vivo expression of an mRNA encoded multi-mechanistic mAb combination against Staphylococcus aureus and protection in disease model Presentation Details Oral Presentation Session Title: Around the Lab in 80 Ways: A Journey Through Innovative Therapeutics Date: Saturday 12 April 2025 Time: 11 AM – 12 PM CEST Location: Hall 13 Abstract Title Low dose of a novel SARS-COV-2 mRNA VLP vaccine elicits equivalent cell-mediated immunity to a licensed mRNA vaccine Presentation Details Poster Presentation Session Title: COVID-19 Date: Saturday 12 April 2025 Time: 12 PM – 1:30 PM CEST Location: Poster Area in Hall D Abstract Title A Bispecific Monoclonal Antibody Targeting Psl and PcrV Enhances Bronchiectasis Patient Neutrophil-Mediated Killing Of Pseudomonas aeruginosa Presentation Details Poster Presentation Session Title: Drug Discovery and New Compounds Mechanisms of Action & Spectrum, Preclinical Data & Basic Pharmacology Date: Sunday 13 April 2025 Time: 12 PM – 1:30 PM CEST Location: Poster Area in Hall D Abstract Title Broad coverage of antibiotic-resistant Klebsiella pneumoniae by multi-specific antibodies against the lipopolysaccharide O-antigen Presentation Details Poster Presentation Session Title: Drug Discovery and New Compounds Mechanisms of Action & Spectrum, Preclinical Data & Basic Pharmacology Date: Sunday 13 April 2025 Time: 12 PM – 1:30 PM CEST Location: Poster Area in Hall D Abstract Title Real-World Evidence: Respiratory Infections Abstract Title Comparative outcomes of hMPV, influenza, and SARS-CoV-2 infections in haematologic malignancy patients: A matched cohort analysis Presentation Details Late-Breaking Poster Presentation Session Title: Outbreaks and Public Health Emergencies Date: Tuesday 15 April 2025 Time: 12 PM – 1:30 PM CEST Location: Poster Area in Hall D Abstract Title Matched cohort study comparing the impact of RSV, influenza, and SARS-CoV-2 infections in patients with haematological malignancies Presentation Details Late-Breaking Poster Presentation Session Title: Outbreaks and Public Health Emergencies Date: Tuesday 15 April 2025 Time: 12 PM – 1:30 PM CEST Location: Poster Area in Hall D Abstract Title Similar proportions and temporal patterns of influenza, RSV, and hMPV among ESKD patients tested between 2020-2023 Presentation Details Poster Presentation Session Title: Influenza and Respiratory Viruses Date: Saturday 12 April 2025 Time: 12 PM – 1:30 PM CEST Location: Poster Area in Hall D Abstract Title Characterization of hMPV and RSV cases in the French national hospital claims database during the 2022-2023 season Presentation Details Poster Presentation Session Title: Influenza and Respiratory Viruses Date: Saturday 12 April 2025 Time: 12 PM – 1:30 PM CEST Location: Poster Area in Hall D Abstract Title Shifting viral landscapes: the impact of SARS-CoV-2 on hospitalization, ICU admission, and mortality in respiratory infections among older adults in Valencia, Spain Presentation Details Poster Presentation Session Title: Influenza and Respiratory Viruses Date: Saturday 12 April 2025 Time: 12 PM – 1:30 PM CEST Location: Poster Area in Hall D Abstract Title Respiratory syncytial virus (RSV)-associated hospitalised influenza-like illness (ILI) and clinical progression in adolescents and adults in Valencia, Spain, 2014/2015-2019/2020: the VALSARI study Presentation Details Poster Presentation Session Title: Influenza and Respiratory Viruses Date: Saturday 12 April 2025 Time: 12 PM – 1:30 PM CEST Location: Poster Area in Hall D Abstract Title Real-world effectiveness of live attenuated (LAIV) and inactivated (IIV) influenza vaccines in children: a systematic literature review (SLR) and network meta-analysis (NMA) Presentation Details Poster Presentation Session Title: Influenza and Respiratory Viruses Date: Saturday 12 April 2025 Time: 12 PM – 1:30 PM CEST Location: Poster Area in Hall D Abstract Title COVID-19 mAbs Abstract Title Pharmacokinetics and immunogenicity of AZD7442 (Tixagevimab/Cilgavimab) in hospitalised COVID-19 patients: results from the DisCoVeRy trial Presentation Details Oral Presentation Session Title: New developments in prophylaxis and treatment of COVID-19 Date: Saturday 12 April 2025 Time: 11:00 Location: Hall 6 Abstract Title A threshold of protection model for monoclonal antibody pre-exposure prophylaxis against COVID-19 enabling rapid development for future SARS-CoV-2 variants Presentation Details Poster Presentation Session Title: COVID-19 Date: Saturday 12 April 2025 Time: 12 PM – 1:30 PM CEST Location: Poster Area in Hall D Notes AstraZeneca AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca. Contacts For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here. References 1. GBD 2019 Antimicrobial Resistance Collaborators. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022 Dec 17;400(10369):2221-2248. 2. Tkaczyk C, Newton M et al. In vivo expression of an mRNA encoded multi-mechanistic mAb combination against Staphylococcus aureus and protection in disease model. Oral Presentation. ESCMID Global 2025; Vienna, Austria. 2025. 3. Long MB, Gilmour A et al. A bispecific monoclonal antibody targeting Psl and PcrV enhances bronchiectasis patient neutrophil-mediated killing of Pseudomonas aeruginosa. Poster Presentation #P3642. ESCMID Global 2025; Vienna, Austria. 2025. 4. Doyle M, Smith A et al. Broad coverage of antibiotic-resistant Klebsiella pneumoniae by multi-specific antibodies against the lipopolysaccharide O-antigen. Poster Presentation #P2377. ESCMID Global 2025; Vienna, Austria. 2025. 5. Stuurman AL, Enxing J et al. Real-world effectiveness of live attenuated (LAIV) and inactivated (IIV) influenza vaccines in children: a systematic literature review (SLR) and network meta-analysis (NMA). Poster Presentation #P0120. ESCMID Global 2025; Vienna, Austria. 2025. 6. Salmanton-Garcia J, Marchesi F et al. Comparative outcomes of hMPV, influenza, and SARS-CoV-2 infections in haematologic malignancy patients: a matched cohort analysis. Poster Presentation #P5067. ESCMID Global 2025; Vienna, Austria. 2025. 7. Marchesi F, Salmanton-Garcia J et al. Matched cohort study comparing the impact of RSV, influenza, and SARS-CoV-2 infections in patients with haematologic malignancies. Poster Presentation #P5066. ESCMID Global 2025; Vienna, Austria. 2025. 8. Mira-Iglesias A, Herring T et al. Respiratory syncytial virus (RSV)-associated hospitalisations and clinical progression in adolescents and adults in Valencia, Spain, 2014/2015–2019/2020: the VALSARI study. Poster Presentation #P0131. ESCMID Global 2025; Vienna, Austria. 2025. 9. Mira-Iglesias A, Herring T et al. Respiratory syncytial virus (RSV)-associated hospitalisations and clinical progression in adolescents and adults in Valencia, Spain, 2014/2015–2019/2020: the VALSARI study. Poster Presentation #P0132. ESCMID Global 2025; Vienna, Austria. 2025. 10. Binh Luong Nguyen L, et al. Characterisation of hMPV and RSV hospitalisations in the French national hospital claims database during the 2022-2023 season. Poster Presentation #P0183. ESCMID Global 2025; Vienna, Austria. 2025. 11. Mallah N, Pardo-Seco J, et al. Effectiveness of universal prophylaxis with nirsevimab for prevention of infant hospitalisations due to respiratory syncytial virus : full 2023-24 season analysis of the NIRSE-GAL study. Poster Presentation #P0124. ESCMID Global 2025; Vienna, Austria. 2025. 12. Swanson PA II, Padilla M et al. Low dosage of a novel SARS-COV-2 mRNA VLP vaccine elicits equivalent cell-mediated immunity to a licensed mRNA vaccine. Poster Presentation # P0482. ESCMID Global 2025; Vienna, Austria. 2025. 13. Edge R, Matthews S et al. A validated threshold of protection model for monoclonal antibody pre-exposure prophylaxis against COVID-19 enabling rapid development for future SARS-CoV-2 variants. Poster Presentation #P0448. ESCMID Global 2025; Vienna, Austria. 2025. Corporate and financial

疫苗上市批准免疫疗法临床研究信使RNA

2025-03-14

·Endpoints

Altimmune to put its incretin into addiction trials; Tarsus aims to raise $125M

Plus, news about Heidelberg, Accropeutics, Allarity Therapeutics, Cadrenal and Inovio: Altimmune to test its incretin in addiction : Following the path set by Novo Nordisk last week , Altimmune said Thursday at its R&D Day that it plans to begin trials of its injectable GLP-1/glucagon agonist pemvidutide in alcohol use disorder as well as alcoholic liver disease. Stifel analysts wrote in a note on Thursday that Altimmune has animal data that suggest pemvidutide could reduce daily alcohol intake by around half. They also cautioned that additional data would be needed to validate the hypothesis. — Elizabeth Cairns Tarsus Pharmaceuticals’ expected $125 million stock sale: The drugmaker said the funds from the public offering will be used to support the US commercialization of Xdemvy, eye drops for irritation caused by tiny mites. Tarsus also said the funds will be used to advance its experimental ocular rosacea and lyme disease drugs. — Lei Lei Wu Heidelberg amends royalty deal: The company signed an agreement with HealthCare Royalty a year ago to provide royalties to Zircaix, or TLX250-CDx, an imaging agent for some kidney cancers. While the total value of the milestones remains the same at $90 million, the companies changed the deal so that Heidelberg will receive $20 million immediately rather than get $15 million as a sales milestone. They also reduced the FDA approval milestone to $70 million from $75 million. (That milestone will be further reduced if approval comes after 2025.) Heidelberg licensed the drug to Telix in 2017, and a rolling FDA submission was initiated in 2023. — Max Gelman Accropeutics raises $12M to fund IBD asset : The Series B-plus round was led by Shenzhen Capital Group and is set to extend the biotech’s cash runway into the second half of next year. The proceeds will be used for the ongoing Phase 1b trial of Accropeutics’ RIPK2 inhibitor, known as AC-101, in ulcerative colitis. Accropeutics also has a mid-stage TYK2/JAK1 inhibitor in development for psoriasis and a RIPK1 inhibitor for graft-versus-host disease. — Elizabeth Cairns Allarity Therapeutics settles with SEC: The company will pay $2.5 million to the Securities and Exchange Commission after the regulator alleged Allarity executives concealed from investors that the FDA had recommended against approving dovitinib, an experimental cancer therapy. The company did not admit or deny the allegations. — Jaimy Lee Cadrenal is still seeking a partner for tecarfarin: It wants help advancing the oral vitamin K antagonist into a pivotal trial for patients with left ventricular assist devices and other rare cardiovascular conditions. — Jaimy Lee Inovio’s DNA therapy is durable in early trial : The company said Thursday that a Phase 1 trial proves the concept of its so-called DMAbs. The DNA plasmids encoding antibodies derived from Evusheld, AstraZeneca’s Covid-19 prophylactic, were given to patients and were translated into the proteins by the patient’s own cells. All subjects who reached week 72 had biologically relevant levels of the antibodies, according to Inovio, and the expressed DMAbs bound to the SARS-CoV-2 spike protein confirmed functional activity. However, the company did not say whether the approach prevented infections . — Elizabeth Cairns

临床1期临床结果

2025-02-24

·BioSpace

FDA Shoots Down Invivyd’s Bid to Expand EUA for COVID-19 Antibody

Andrii Yalanskyi/Getty Images Pemgarda has a standing emergency use authorization as a prophylaxis for immunocompromised patients, but FDA’s stringent requirements for antibody activity boxed out its potential use as a post-exposure treatment. The FDA declined to expand the emergency use authorization for Invivyd’s anti-SARS-CoV-2 bispecific antibody Pemgarda, the company said Monday. Invivyd had applied for expanded use to include treatment of mild and moderate COVID-19 for immunocompromised persons without an alternative treatment option. The emergency use authorization (EUA) for Pemgarda as a pre-exposure prophylactic, which the company received from the FDA last March, is still in effect. The Waltham, MA–based company made the announcement Monday morning. By Monday afternoon, Invivyd’s stock had lost about one-third of its value, falling from $1.77 per share at open to about $1.21 per share . The news was perhaps not much of a surprise to analysts. “This outcome underscores the FDA’s insistence on superior antiviral activity for treatment indications and highlights the challenges of re-purposing monoclonal antibodies amid an evolving viral landscape,” Patrick Trucchio, an analyst with HC Wainwright, wrote in a note Monday. Pemgarda is currently the only pre-exposure prophylactic for COVID-19 on the market. AstraZeneca’s Evusheld was approved in 2021 but was withdrawn from the market in 2023 when it lost its effectiveness against emerging SARS-CoV-2 variants. Invivyd’s pipeline is mostly focused on antibody treatments and prophylaxis for COVID-19 as an alternative to vaccines for immunocompromised patients. While Pemgarda remains without a full FDA approval, the company is continuing a Phase I clinical trial on a next-generation antibody COVID-19 prophylactic, called VYD2311, which it sees as a successor to Pemgarda. Invivyd announced promising initial data for VYD2311 earlier this month. “Deploying a new protective mAb in the future that has the convenience and scalability of current vaccine boosts but with substantially more attractive protection, safety, and durability [than Pemgarda] would be a massive step change in medical value for millions of Americans in need,” Invivyd Chief Commerical Officer Tim Lee said in a statement outlining that data.

疫苗上市批准临床1期紧急使用授权信使RNA

100 项与西加韦单抗/替沙格韦单抗相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
新型冠状病毒感染	美国	AstraZeneca PLC	2021-12-08

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
冠状病毒感染	临床1期	美国	AstraZeneca PLC	2021-11-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05166421 (CTgov)	临床1期	冠状病毒感染	224	AZD8895+AZD1061 (Treatment A: AZD8895 and AZD1061 (Coformulation, Clonal Cell Line Material))	醖襯憲餘憲網糧醖衊願(鏇鬱糧鏇餘獵襯廠鏇糧) = 餘範餘願淵選餘壓觸鬱淵衊鹹淵鹹鹹網蓋築構 (餘鏇鏇網遞淵遞積餘選, 43.12) 更多	-	2024-11-25
				AZD8895+AZD1061 (Treatment B: AZD8895 and AZD1061 (Separate Vials, Clonal Cell Line Material))	醖襯憲餘憲網糧醖衊願(鏇鬱糧鏇餘獵襯廠鏇糧) = 夢遞鏇鏇觸鹽積淵壓製淵衊鹹淵鹹鹹網蓋築構 (餘鏇鏇網遞淵遞積餘選, 38.96) 更多
NCT05184062 (CTgov)	临床2期	新型冠状病毒感染	272	600 mg AZD7442 IV (AZD7442)	廠繭鏇淵繭積膚壓繭簾 = 鹹糧鏇壓顧鏇構廠網構觸衊壓夢糧糧醖築積顧 (餘鹹壓積餘鑰遞獵鏇簾, 網選願襯襯鹽選淵窪鑰 ~ 夢壓糧衊繭鹹願壓構選) 更多	-	2024-11-21
				600mg placebo IV (Placebo)	廠繭鏇淵繭積膚壓繭簾 = 獵鹹襯簾鬱鏇齋鏇蓋積觸衊壓夢糧糧醖築積顧 (餘鹹壓積餘鑰遞獵鏇簾, 網簾憲簾醖鏇憲廠願壓 ~ 構齋夢築範構網遞鏇範) 更多
NCT05375760 (ENDURE, CTgov)	临床2期	新型冠状病毒感染	251	AZD7442 (AZD7442: 600mg ONCE / 300mg Q3M)	憲構鬱築遞願醖鑰構鹹 = 糧遞衊齋築構憲鹽蓋淵廠醖憲繭夢製膚鹽顧構 (衊簾選築顧壓淵選觸鬱, 膚築壓顧獵網選構衊襯 ~ 壓壓壓顧鑰淵鬱廠淵廠) 更多	-	2024-10-23
				AZD7442 (AZD7442: 1200 mg ONCE / 600mg Q6M)	憲構鬱築遞願醖鑰構鹹 = 壓襯鏇願憲艱膚範繭構廠醖憲繭夢製膚鹽顧構 (衊簾選築顧壓淵選觸鬱, 夢醖糧選蓋遞鬱遞鹽夢 ~ 淵鏇顧餘鹽鑰製選糧範) 更多
NCT04507256 (CTgov)	临床1期	新型冠状病毒感染	60	placebo (Pooled Placebo)	糧醖艱網艱網積顧範鹹 = 簾夢獵顧鏇積積餘願積艱糧積廠蓋鏇醖願鏇積 (鹽糧鹽繭積襯遞醖鏇夢, 築衊憲獵鬱獵顧觸築壓 ~ 鏇鬱築壓獵糧築壓淵願) 更多	-	2024-10-18
				AZD7442 (AZD7442 300 mg, IM)	糧醖艱網艱網積顧範鹹 = 襯膚壓糧遞蓋廠窪鑰範艱糧積廠蓋鏇醖願鏇積 (鹽糧鹽繭積襯遞醖鏇夢, 鹽淵選範齋膚醖廠醖觸 ~ 醖膚廠網鹽夢憲製遞醖) 更多
NCT05780437 (CTgov)	临床3期	新型冠状病毒感染	1,455	AZD7442+Remdesivir (AZD7442 Plus SOC)	遞餘餘簾鬱獵觸鹹膚獵 = 糧觸簾鏇齋窪廠淵蓋壓齋鏇糧夢選積築鹽獵糧 (願製範鑰廠鑰夢淵獵廠, 鏇築築繭獵齋顧衊鏇餘 ~ 遞網鑰衊範膚積獵製繭) 更多	-	2024-07-30
				Placebo+Remdesivir (Placebo Plus SOC)	遞餘餘簾鬱獵觸鹹膚獵 = 餘膚築襯願築餘憲簾糧齋鏇糧夢選積築鹽獵糧 (願製範鑰廠鑰夢淵獵廠, 築鏇鬱遞願艱蓋鏇鑰夢 ~ 構夢鑰願製積簾遞顧鑰) 更多
NCT04625725 \| NCT04625972 (PROVENT and STORM CHASER, Pubmed)	临床3期	新型冠状病毒感染	-	AZD7442 300 mg	獵鏇觸憲選淵蓋鏇醖鏇(憲鹹醖顧遞襯遞觸窪襯) = 製糧壓壓選鏇艱壓獵鏇積獵獵網餘積憲衊蓋構 (廠網淵製顧構鏇築繭襯 ) 更多	积极	2024-06-01
				Placebo	獵鏇觸憲選淵蓋鏇醖鏇(憲鹹醖顧遞襯遞觸窪襯) = 糧鬱糧廠壓網鏇醖淵鬱積獵獵網餘積憲衊蓋構 (廠網淵製顧構鏇築繭襯 ) 更多
AASLD2023	N/A	-	1,149	Evusheld	襯遞夢糧餘顧願膚鬱鹹(鹹網齋窪選鑰壓繭艱鹹) = 積衊築築鑰遞憲憲膚襯構蓋築網範構醖積製憲 (鬱廠網醖淵壓窪鬱遞淵 ) 更多	-	2023-11-10
IMS2023	N/A	多发性骨髓瘤	55	Tixagevimab/cilgavimab (Evusheld)	廠醖壓醖夢簾觸範糧網(夢鏇選夢餘膚範獵鑰餘) = Overall, 5 patients (9%) were diagnosed with COVID-19 at a median of 1 month (range 1-2) after receiving tixagevimab/cilgavimab. All of these patients received nirmatrelvir/ritonavir (Paxlovid) for 5 days as outpatients along with supportive care as per standard clinical practice and recovered completely. There were no COVID-19-related hospitalization or deaths. 淵願積憲築糧齋齋網顧 (齋淵壓構窪淵廠製廠鹽 ) 更多	-	2023-09-26
IMS2023	N/A	多发性骨髓瘤	44	Tixagevimab/cilgavimab	鹽夢衊夢襯鬱願積衊範(簾襯選鬱鏇夢襯夢襯選) = 築憲淵醖遞繭鹹憲壓廠選製鬱遞鬱鹹蓋觸範鏇 (鬱鹹鬱廠鏇鏇簾鹽築鑰 )	-	2023-09-26
NCT04723394 (TACKLE, Pubmed \| Infect Dis Ther)	临床3期	新型冠状病毒感染	-	AZD7442 (tixagevimab/cilgavimab)	獵範淵鹽築願觸鏇鑰遞(窪衊淵憲選鏇窪襯願鑰) = 範鏇積獵齋齋襯齋繭製鹽範鹹醖窪範選構鏇窪 (膚積淵鹽觸夢壓窪襯齋 ) 更多	积极	2023-09-01
				Placebo	獵範淵鹽築願觸鏇鑰遞(窪衊淵憲選鏇窪襯願鑰) = 鑰鹹鹽獵範鹹夢餘衊鹽鹽範鹹醖窪範選構鏇窪 (膚積淵鹽觸夢壓窪襯齋 ) 更多